You're worried about the economy and want to take action to prepare your business for the worse?
Now is the perfect time to take a look at your burn rate and cut out the fat.
Here is our 6-step plan to get you started:
At Finro, we track 180+ AI agent companies across 10 functional use cases. If you’re building or backing one, we can help you benchmark, model, and price it right.
Get it here: https://t.co/NVqSgarr6b
Valuation ≠ heat.
Dev tools dominate in capital + volume, sure.
But some low-key AI agent niches? Fewer players, higher valuations.
It’s not just the tech. It’s:
→ Capital flow
→ Winner density
→ Use case defensibility
That’s where it gets interesting.
Not all AI agents are valued the same.
We analyzed 180+ startups — same models, same tech.
But revenue multiples?
3x in one niche, 18x in another.
Why?
→ Use case
→ Workflow depth
→ Capital efficiency
→ Investor perception
Benchmark by function or don’t benchmark at all.
“PropTech is booming!”
Yeah, but which PropTech?
AI → High multiples.
Property mgmt → Steady.
Construction → Big potential, slow adoption.
Not all PropTech is created equal.
Investors used to ask: “Is AI a bubble?”
Now it’s: “Which niche wins?”
- AI still at 23.4x multiples, but gaps are huge:
- Infra – still on top.
- Cyber & Health – long-term winners.
- LLMs – adjusting to reality.
Not all AI startups are equal.
Pre-seed isn’t about napkin sketches anymore.
It’s about real traction, data-driven forecasts, and a clear growth strategy.
Prove your concept with actual user data and market validation.
PropTech ≠ SaaS.
- SaaS multiples don’t apply.
- Real estate is capital-intensive.
- Margins & growth vary.
- Scaling takes longer.
Get the valuation right—or get ghosted.
AI valuations tell you where the money’s moving.
- Infra still leads.
- Cyber & Health Tech are surging.
- LLMs? Market reality is setting in.
- Marketing & HR Tech – unexpected winners.
Still, using last year’s benchmarks? You’re already behind.
Biotech valuations make no sense—until they do.
A company can be worth billions before making a dollar.
Why?
Because trials, not revenue, drive valuation.
✅ FDA approval? 10x valuation.
❌ Failed trial? Billions gone.
Fintech valuations are all over the place.
Some are getting crushed. Others? Pulling in massive premiums.
But valuations follow a pattern. Stop guessing. Get real data.
200+ fintech companies—public, private, and M&A. All multiples in one dataset.
https://t.co/mD54zLeIKe
Bad models kill startups.
We know tech, founders, and exactly what investors want.
At Finro, we break down every detail and reconstruct it into a strategy that benefits both you and your investors.
Ready to build a financial model that really reflects your potential?
AI is thriving now!
In 2025, AI companies average a 23.4x revenue multiple. Driven by Market demand, innovation, and real-world impact.
Our latest analysis dives into 180+ AI companies—public, private, and M&A. Curious about the trends?
Read here: https://t.co/NooKCKiMFD
Exploring the value behind AI startups?
Our AI Startup Valuation Report unravels the latest trends and strategies, offering insights from healthcare to fintech.
It's a thoughtful read for those steering through the AI investment landscape.
https://t.co/JYpMKOkZBs
One month of positive cash flow ≠ financial stability.
The business is still underwater in cumulative cash flow.
The real goal should be reaching a cumulative cash flow break even.
Real financial freedom is generating more cash since the start than you spent.
Insurtech peaked in 2021, offering what we sought: digital, distributive services.
Yet, post-2021:
▶️ funding dropped 73% to $4.6B.
▶️ multiples dropped from 50x to 9.7x.
Can AI revive it?